Checkpoint kinase 1 activation enhances intestinal epithelial barrier function via regulation of claudin-5 expression

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Watari, Akihiro ^a   Hasegawa, Maki ^a   Yagi, Kiyohito ^a   Kondoh, Masuo ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ATM PROTEIN; ATR PROTEIN; CAFFEINE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; CHECKPOINT KINASE INHIBITOR; CLAUDIN 5; DAUNORUBICIN; DNA; GAMMA INTERFERON; REBECCAMYCIN; SMALL INTERFERING RNA; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARBAZOLE DERIVATIVE; CHEK1 PROTEIN, HUMAN; CLDN5 PROTEIN, HUMAN; PROTEIN KINASE;

ACTIN FILAMENT; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTESTINE FUNCTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; CACO-2 CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INTESTINE MUCOSA; METABOLISM; PHYSIOLOGY;

CACO-2 CELLS; CARBAZOLES; CHECKPOINT KINASE 1; CLAUDIN-5; DAUNORUBICIN; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; PROTEIN KINASES;

EID: 84953776421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145631     Document Type: Article

References (47)

1. Furgason JM, Bahassi el M. Targeting DNA repair mechanisms in cancer. Pharmacology &therapeutics. 2013; 137(3):298-308. Epub 2012/10/31. doi: 10.1016/j.pharmthera.2012.10.009
2. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annual review of biochemistry. 2004; 73:39-85. Epub 2004/06/11. doi: 10.1146/annurev.biochem.73.011303.073723
3. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer cell. 2003; 3 (5):421-9. Epub 2003/06/05.
4. Farquhar MG, Palade GE. Junctional complexes in various epithelia. The Journal of cell biology. 1963; 17:375-412. Epub 1963/05/01.
5. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annual review of physiology. 2006; 68:403-29. Epub 2006/02/08. doi: 10.1146/annurev.physiol.68.040104.131404
6. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annual review of pathology. 2010; 5:119-44. Epub 2010/01/19. doi: 10.1146/annurev.pathol.4.110807.092135
7. Tamura A, Tsukita S. Paracellular barrier and channel functions of TJ claudins in organizing biological systems: advances in the field of barriology revealed in knockout mice. Seminars in cell &developmental biology. 2014; 36:177-85. Epub 2014/10/12. doi: 10.1016/j.semcdb.2014.09.019
8. Furuse M, Tsukita S. Claudins in occluding junctions of humans and flies. Trends in cell biology. 2006; 16(4):181-8. Epub 2006/03/16. doi: 10.1016/j.tcb.2006.02.006
9. Gunzel D, Fromm M. Claudins and other tight junction proteins. Comprehensive Physiology. 2012; 2 (3):1819-52. Epub 2013/06/01. doi: 10.1002/cphy.c110045
10. Sawada N. Tight junction-related human diseases. Pathology international. 2013; 63(1):1-12. Epub 2013/01/30. doi: 10.1111/pin.12021
11. Lu Z, Ding L, Lu Q, Chen YH. Claudins in intestines: Distribution and functional significance in health and diseases. Tissue barriers. 2013; 1(3):e24978. Epub 2014/01/31. doi: 10.4161/tisb.24978
12. Larre I, Lazaro A, Contreras RG, Balda MS, Matter K, Flores-Maldonado C, et al. Ouabain modulates epithelial cell tight junction. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(25):11387-92. Epub 2010/06/11. doi: 10.1073/pnas.1000500107
13. Osanai M, Nishikiori N, Murata M, Chiba H, Kojima T, Sawada N. Cellular retinoic acid bioavailability determines epithelial integrity: Role of retinoic acid receptor alpha agonists in colitis. Molecular pharmacology. 2007; 71(1):250-8. Epub 2006/10/13. doi: 10.1124/mol.106.029579
14. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. The Journal of physiology. 2012; 590(Pt 5):1035-44. Epub 2012/01/06. doi: 10.1113/jphysiol.2011.224568
15. Watari A, Yagi K, Kondoh M. A simple reporter assay for screening claudin-4 modulators. Biochemical and biophysical research communications. 2012; 426(4):454-60. Epub 2012/09/11. doi: 10.1016/j. bbrc.2012.08.083
16. Watari A, Hashegawa M, Muangman T, Yagi K, Kondoh M. Use of cell-based screening to identify small-molecule compounds that modulate claudin-4 expression. Biotechnology letters. 2015; 37 (6):1177-85. Epub 2015/02/24. doi: 10.1007/s10529-015-1791-7
17. Aubel-Sadron G, Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie. 1984; 66(5):333-52. Epub 1984/05/01.
18. Facompre M, Baldeyrou B, Bailly C, Anizon F, Marminon C, Prudhomme M, et al. DNA targeting of two new antitumour rebeccamycin derivatives. European journal of medicinal chemistry. 2002; 37(12):925-32. Epub 2003/03/28.
19. Akagi T, Shishido T, Murata K, Hanafusa H. v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(13):7290-5. Epub 2000/06/15. doi: 10.1073/pnas.140210297
20. Turner JR. Intestinal mucosal barrier function in health and disease. Nature reviews Immunology. 2009; 9(11):799-809. Epub 2009/10/27. doi: 10.1038/nri2653
21. Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W, et al. Tight junctions are membrane microdomains. Journal of cell science. 2000; 113 (Pt 10):1771-81. Epub 2000/04/19.
22. Welsh MJ, Shasby DM, Husted RM. Oxidants increase paracellular permeability in a cultured epithelial cell line. The Journal of clinical investigation. 1985; 76(3):1155-68. Epub 1985/09/01. doi: 10.1172/JCI112071
23. Overgaard CE, Daugherty BL, Mitchell LA, Koval M. Claudins: control of barrier function and regulation in response to oxidant stress. Antioxidants &redox signaling. 2011; 15(5):1179-93. Epub 2011/02/01. doi: 10.1089/ars.2011.3893
24. Reyes JL, Molina-Jijon E, Rodriguez-Munoz R, Bautista-Garcia P, Debray-Garcia Y, Namorado Mdel C. Tight junction proteins and oxidative stress in heavy metals-induced nephrotoxicity. BioMed research international. 2013; 2013:730789. Epub 2013/05/28. doi: 10.1155/2013/730789
25. Akazawa Y, Yuki T, Yoshida H, Sugiyama Y, Inoue S. Activation of TRPV4 strengthens the tight-junction barrier in human epidermal keratinocytes. Skin pharmacology and physiology. 2013; 26(1):15-21. Epub 2012/10/31. doi: 10.1159/000343173
26. Ben-Yehoyada M, Wang LC, Kozekov ID, Rizzo CJ, Gottesman ME, Gautier J. Checkpoint signaling from a single DNA interstrand crosslink. Molecular cell. 2009; 35(5):704-15. Epub 2009/09/15. doi: 10. 1016/j.molcel.2009.08.014
27. Heffernan TP, Simpson DA, Frank AR, Heinloth AN, Paules RS, Cordeiro-Stone M, et al. An ATR-And Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Molecular and cellular biology. 2002; 22(24):8552-61. Epub 2002/11/26.
28. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. The Journal of biological chemistry. 2003; 278(28):25879-86. Epub 2003/05/10. doi: 10.1074/jbc.M303948200
29. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell. 2002; 111(6):779-89. Epub 2003/01/16.
30. Cuadrado M, Martinez-Pastor B, Murga M, Toledo LI, Gutierrez-Martinez P, Lopez E, et al. ATM regulates ATR chromatin loading in response to DNA double-strand breaks. The Journal of experimental medicine. 2006; 203(2):297-303. Epub 2006/02/08. doi: 10.1084/jem.20051923
31. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nature cell biology. 2005; 7(2):195-201. Epub 2005/01/25. doi: 10.1038/ncb1212
32. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell. 2008; 132(2):221-32. Epub 2008/02/05. doi: 10.1016/j.cell.2007.12.013
33. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes &development. 2000; 14(12):1439-47. Epub 2000/06/20.
34. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the bloodbrain barrier in claudin-5-deficient mice. The Journal of cell biology. 2003; 161(3):653-60. Epub 2003/05/14. doi: 10.1083/jcb.200302070
35. Campbell M, Nguyen AT, Kiang AS, Tam LC, Gobbo OL, Kerskens C, et al. An experimental platform for systemic drug delivery to the retina. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(42):17817-22. Epub 2009/10/14. doi: 10.1073/pnas.0908561106
36. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology. 2001; 120(2):411-22. Epub 2001/02/13.
37. Biazik JM, Thompson MB, Murphy CR. Claudin-5 is restricted to the tight junction region of uterine epithelial cells in the uterus of pregnant/gravid squamate reptiles. Anat Rec (Hoboken). 2008; 291(5):547-56. Epub 2008/04/04. doi: 10.1002/ar.20677
38. Amasheh S, Schmidt T, Mahn M, Florian P, Mankertz J, Tavalali S, et al. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells. Cell and tissue research. 2005; 321(1):89-96. Epub 2005/09/15.
39. Jeansonne B, Lu Q, Goodenough DA, Chen YH. Claudin-8 interacts with multi-PDZ domain protein 1 (MUPP1) and reduces paracellular conductance in epithelial cells. Cell Mol Biol (Noisy-le-grand). 2003; 49(1):13-21. Epub 2003/07/04.
40. Amasheh S, Milatz S, Krug SM, Bergs M, Amasheh M, Schulzke JD, et al. Na+ absorption defends from paracellular back-leakage by claudin-8 upregulation. Biochemical and biophysical research communications. 2009; 378(1):45-50. Epub 2008/11/13. doi: 10.1016/j.bbrc.2008.10.164
41. Gow A, Southwood CM, Li JS, Pariali M, Riordan GP, Brodie SE, et al. CNS myelin and sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell. 1999; 99(6):649-59. Epub 1999/12/28.
42. Gow A, Davies C, Southwood CM, Frolenkov G, Chrustowski M, Ng L, et al. Deafness in Claudin 11-null mice reveals the critical contribution of basal cell tight junctions to stria vascularis function. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2004; 24(32):7051-62. Epub 2004/08/13. doi: 10.1523/JNEUROSCI.1640-04.2004
43. Hering NA, Schulzke JD. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis. 2009; 27(4):450-4. Epub 2009/11/10. doi: 10.1159/000233283
44. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56(1):61-72. Epub 2006/07/11. doi: 10.1136/gut.2006.094375
45. Westbrook AM, Szakmary A, Schiestl RH. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutation research. 2010; 705(1):40-59. Epub 2010/03/20. doi: 10.1016/j.mrrev.2010.03.001
46. Schumann M, Kamel S, Pahlitzsch ML, Lebenheim L, May C, Krauss M, et al. Defective tight junctions in refractory celiac disease. Annals of the New York Academy of Sciences. 2012; 1258:43-51. Epub 2012/06/27. doi: 10.1111/j.1749-6632.2012.06565.x
47. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2013; 11(9):1075-83. Epub 2013/07/16. doi: 10.1016/j.cgh.2013.07.001